stockportfolio.pro
Stocks / ABT vs RGEN
ABT vs RGEN
Abbott Laboratories and Repligen Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Abbott Laboratories (ABT) | Repligen Corporation (RGEN) | |
|---|---|---|
| Market cap | $158.9B | $7.4B |
| Revenue (latest FY) | $44.33B | $738.26M |
| Net income (latest FY) | $6.52B | $48.89M |
| Revenue growth (5y CAGR) | 5.1% | 15.0% |
| Net margin | 14.7% | 6.6% |
| Return on equity | 12.5% | 2.3% |
| P/E ratio | 25.3 | 144.0 |
| Dividend yield | 2.8% | — |
| Profitable years (of last 10) | 10 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABT — free Open RGEN — freeFrequently asked questions
Which is bigger, ABT or RGEN?
Abbott Laboratories is larger by market capitalization — $158.9B versus $7.4B.
Which grows faster, ABT or RGEN?
Over the last five fiscal years, Repligen Corporation grew revenue faster — 15.0%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.